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osting by EAbstract Monogenic forms of diabetes are still rare and not well understood. Their prevalence
among children and young adults at diagnosis is thought to be between 1% and 2% of cases of dia-
betes. However, awareness of these conditions may be lacking, and screening for them genetically is
not routinely undertaken, even when the clinical picture may point to their probability. The aim of
this work is to identify the indicators for suspecting cases of monogenic diabetes beyond the neo-
natal period in children and young adults in Saudi Arabia, and to provide a draft for baseline inves-
tigations for those suspected cases, depending on available resources. The implications of the
diagnosis of such conditions would be better management of cases, providing genetic counseling
to families and planning health resources.
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Will my child need insulin for life?
When a family is given the diagnosis of diabetes for their
child, this is the most commonly asked question we hear where
we practice. Type 1 diabetes remains the most common type of
diabetes diagnosed in children and young adults. Therefore, we
usually advise parents that insulin will be needed for life. There
is however an increasing incidence of type 2 diabetes with the
global endemic of obesity and other rare types of monogenic
diabetes. In these conditions, insulin may not be needed for
life.
In Saudi Arabia, there is increased consanguinity with ﬁrst
degree cousin marriages, which is not only allowed but socially
favored. Hence genetic disorders like monogenic diabetes may
be more prevalent. Therefore, it would be logical to consider
monogenic forms of familial diabetes in the differential
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monogenic diabetes is not known in Saudi Arabia.
2. Aim of the work
The aim of the current work is to look at a possible algo-
rithm for diagnosing monogenic diabetes among children
and young adults beyond the neonatal period, in an area of
high consanguinity in the middle-east. The literature will be
searched for evidence of when to suspect monogenic diabetes
and according to the clinical picture, what genetic tests to
request.
We will also search the literature for the best management
of diagnosed cases, genetic counseling of families and implica-
tions for other family members. Cases of monogenic diabetes
presenting in the neonatal period will not be discussed, as they
are beyond the scope of this work, and the main aim is to dif-
ferentiate type 1 diabetes from monogenic forms.
2.1. What is monogenic diabetes?
Monogenic diabetes is not a single diagnosis. It is a group of
disorders mostly dominantly inherited, causing beta cell dys-
function [1]. They are usually caused by single gene defects that
can occur de novo in a child, but more commonly, a family his-
tory is present [2]. The importance of making the diagnosis is
that there may be implications for the child in the form of a
change in treatment from insulin to oral hypoglycemics, and
for the family in diagnosing other family members and coun-
seling for future pregnancies. The health care implications
noted are the change to a less costly treatment and, in some
cases, no need for treatment at all.
2.2. Clinical picture
Mostly presenting with hyperglycemia, and being in the pedi-
atric age group, patients are given the diagnosis of type 1 dia-
betes [3]. The point that may direct the attention of the
pediatrician/diabetologist to the possibility of monogenic dia-
betes is the occurrence of diabetes in the family, in particular a
dominant type of inheritance such as 2–3 generations of diabe-
tes [4]. This criterion can sometimes be challenging, with the
increasing number of families with type 2 diabetes. However,
as maturity onset diabetes of the young (MODY) genes do
not exclude type 2 diabetes [5], a positive family history should
still be taken into consideration.
It is therefore our view that more weight should be placed
on a typical autosomal dominant type of family history of dia-
betes in the family. Other sporadic cases of diabetes in the fam-
ily should also alert the physician to the possibility of genetic
conditions, as a family history of diabetes is found in only
2–4% of type 1 diabetes patients [6]. With positive consanguin-
ity in the family, this gives even more signiﬁcance to a positive
family history. The prevalence of consanguinity in Saudi Ara-
bia is 56%, with ﬁrst-degree cousins reaching up to 40% [7–9].
Although most types of MODY are transferred by autosomal
dominant inheritance, which is generally not increased in con-
sanguineous marriages, there are some autosomal recessive
presenting types, e.g., MODY 4.
The second point that alerts to the possibility of monogenic
diabetes is reduced insulin requirement. Children with type 1diabetes usually require between 0.75 and 1 U/kg/day, and this
can change with activity, diet, age with great individual varia-
tions as well. When children are controlled with around 0.5 U/
kg/day of insulin achieving good control the possibility of
monogenic diabetes has to be raised [10].
The third indicator for testing for MODY is preserved insu-
lin secretion after the honeymoon phase, which is generally
agreed as 3 years from onset of type 1 diagnosis [1]. Endoge-
nous secretion is tested for by detectable C-peptide (>200
nmol/l) with blood glucose level of 8 mmol/l [1]. Insulin level
is not used, as the children are usually on exogenous insulin
as treatment, and C-peptide is a true reﬂection of endogenous
insulin production. The preserved endogenous insulin produc-
tion can explain the lack of ketosis, with hyperglycemia seen in
many cases of monogenic diabetes at presentation [11].
The fourth indicator to consider, which in our view would
be the earliest to detect at presentation, is the absence of auto
antibodies in the pancreatic islets. It is recommended that a
variety of antibodies be measured at the diagnosis of type 1
diabetes, when the results of these antibodies are negative,
the likelihood of monogenic diabetes is greatest. Although
up to 30% of type 1 diabetes cases may have negative antibod-
ies at diagnosis, when all antibodies are negative, together with
the absence of stigmata for insulin resistance, this indicator can
be of most value [12–14].
Type 2 diabetes in children is occurring with increased fre-
quency [15]. MODY genes have been identiﬁed in a number of
cases of type 2 diabetes in adults, and the occurrence of the
gene does not exclude the diagnosis of type 2 diabetes [5].
The diagnosis of type 2 diabetes in children may not be correct,
however, if the child is of normal body weight [16], with no
signs of insulin resistance specially acanthosis nigricans [17],
and with normal fasting levels of C-peptide [18].2.3. Clinical indicators for MODY
2.3.1. History
Child is generally well prior to presentation, with possible
coincidental ﬁnding of hyperglycaemia. Positive family history
of 2–3 generations of at least one side of the family carries the
highest value, followed by a positive family history of diabetes
in a parent. Positive consanguinity in the family will generally
increase the likelihood of genetic diseases but the exact inci-
dence in monogenic diabetes has not been reported. Although
most MODY cases are known to be autosomal dominant,
some types, e.g., MODY 4 have presentations of mild diabetes
in heterozygous state.
2.3.2. Examination
The child is usually well on physical examination, with no
signs of diabetic ketoacidosis, which may be the case for up
to 20–40% of cases of type 1 diabetes [19]. The child’s body
mass index (BMI) is within an acceptable range for age and
sex.
No clinical stigmata of insulin resistance as acanthosis
nigricans.
No manifestations of syndromic insulin resistance, e.g.,
hirsuitism, lipodystrophy, etc.
On follow up, metabolic control is achieved with low doses
of insulin and minimal effort regarding diet control and exer-
cise, at least initially.
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Hyperglycemia may be severe, but may be mild and only with
fasting in some cases of monogenic diabetes [1]. Ketones are
usually negative on presentation, but may be present [19].
Auto antibodies against pancreatic islets are negative [12].
On follow up; residual C-peptide levels beyond the honeymoon
period.
In our opinion, if a child or young adult fulﬁls most of the
above criteria, he or she will beneﬁt from genetic testing for
MODY.
Now that we suspect, what to do?
When faced with a clinical scenario, as above, it is tempt-
ing to look for a ‘‘genetic diagnosis for MODY’’. Some ge-
netic laboratories provide a clinical sheet to be ﬁlled in by
the referring physician, which would include history, clinical
ﬁndings and biochemical investigations. Experts in these labs
will then direct the testing towards the most probable diagno-
sis, based on these ﬁndings. This may not be the case in all
centers when a speciﬁc test needs to be requested; otherwise
it will be ﬁnancially unacceptable to run the panel for the full
range of monogenic diabetes. It will therefore be useful to
have clinical and laboratory indicators for different types of
MODY, and hence, advise the lab as to which diagnostic test
is required.
Neither types 1 and 2 diabetes has a diagnostic test, whereas
monogenic diabetes can be diagnosed by genetic tests in about
80% of cases at present [1].
2.4. Indicators for type of MODY
Some forms are easily distinguishable, owing to major clinical
ﬁndings, e.g., MODY 4, Mutation of insulin promoter factor-1
a, which is required for both endocrine and exocrine functions
of the pancreas. Therefore, cases of MODY 4 will have exo-
crine pancreatic insufﬁciency, as well as being extremely rare
[20,21].
Another type, MODY 5, is caused by mutation of HNF 1b,
which is a transcription factor that can cause extra pancreatic
diseases such as uterine hypoplasia in females, and hypospadi-
us in males. Other distinctive ﬁndings are non diabetes related
renal problems like oligomeganephrons, renal cysts and hypo-
plastic glomerulonephric cysts [22]. These ﬁndings can be de-
tected by abdominal and renal ultrasound, which are non
invasive and cost effective investigations and can guide to-
wards the diagnosis.
Other forms of monogenic diabetes, MODY 3 (most com-
mon type), MODY 1 and glucokinase deﬁciency (GKD) do
not have clinically distinct features, and may need an oral glu-
cose tolerance test (OGTT) for diagnosis.
2.5. Value of OGTT for diagnosis of MODY
Type 1 diabetes presents with insidious onset of polyuria, poly-
dypsia, polyphagia and loss of weight or acute onset of DKA
[23]. Oral glucose tolerance is not usually required for diagno-
sis, as random venous blood glucose is usually above
11.1 mmol/l, which is the cut off for acceptable as deﬁned by
WHO criteria for diagnosing diabetes [24].
When suspecting a case to be monogenic diabetes or type 2
diabetes, an OGTT may help to reach a diagnosis and narrowthe differential to the type of MODY. The test, however, re-
quires the child to be present in the ward/day unit for a few
hours after an overnight fast, and may be difﬁcult for small
children. It is not without complications, especially rebound
hypoglycemia if hyper-insulinism is an association, and it re-
quires monitoring of the child.
Stride et al. [25] assessed Oral Glucose tolerance in a multi
center trial involving 362 individuals with genetically diag-
nosed MODY, including 162 patients below 20 years of age.
In this study, patients were off treatment either as insulin or
oral hypoglycemics for 1 week prior to the OGTT. This is
not feasible when a child is newly diagnosed as having diabe-
tes, and guidelines require the start of insulin treatment unless
a molecular diagnosis proves MODY, and then the gradual
withdrawal of insulin, followed by the introduction of oral
agents, is started under strict supervision. Children as young
as 2 years of age experienced OGTT during this study. This,
however, needs to be performed only in highly specialized
centers.
However, what is learned from this study is very valuable.
The authors recommend that impaired fasting glucose alone,
without the need for OGTT, may be helpful in cases of
GKD. More than 70% of patients with GKD at less than
20 years of age had impaired fasting blood glucose. This may
not be noted in very young children, but impaired fasting levels
were seen on retesting.
If patients with GKD underwent OGTT, the increment of
plasma glucose was noted to be small (less than 3.0 mmol/l)
compared to patients with hepatocyte nuclear 1 alpha (HNF
1a) [25]. HNF 1a patients, however, had normal fasting
blood glucose in all cases below 20 years of age. Some of
them had normal glucose tolerance, especially those below
10 years of age. However, the overall conclusion drawn from
the study when including all age groups has shown a large
increment in blood glucose during OGTT (>3.0 mmol/l)
[25].
Another mutation of HNF 4a gene causes similar clinical
picture to HNF 1a but are less common [11]. Patients have
lower renal threshold, and may present at an older age than
HNF 1a. This group of patients’ OGTT was not studied by
Stride et al.
The study by Stride et al. has shed ﬁrst light on the glucose
tolerance in cases of MODY, and also provided information
about progression of different types. It would be most useful
to screen family members of affected individuals before send-
ing them for genetic testing, or to test individuals early on in
the course of the disease, to decide which test to send for
screening.
We see this as most feasible in young adults who are meta-
bolically stable and with no evidence of ketosis. They have to
be educated about screening for blood glucose and ketones
and reporting to hospital immediately in cases of hyperglyca-
emia or positive ketonaemia or ketonuria.
We do not propose to keep children off treatment for a
week prior to an OGTT test when one doubts the diagnosis
of diabetes, as type 1 remains the most common cause. If there
is strong family history of MODY in family and criteria previ-
ously deﬁned, treatment can be started then blood sent for ge-
netic testing. Initially for HNF 1a gene the most common of
MODY, or the glucokinase gene, if the child has impaired fast-
ing glucose.
Table 1 summary of clinical criteria of different types of MODY and relative prevalence in UK [1].
Inheritance Number of families
identiﬁed in UK
Typical age of
presentation in
pediatric clinic
(range)
Typical glucose at
presentation (range)
mmol/l
Other clinical features
HNF 1a
(MODY3)
Dominant 197 14 (4–18) 17 (11–26) Large increment in an OGTT (2–0 h
usually > 5 mmol/l)
Low renal threshold
Progressive hyperglycaemia with age
Sensitive to sulphonylureas
HNF 4a (MODY1) Dominant 22 17 (5–18) 15 (9–20) Similar to HNF 1a but renal
threshold normal
Glucokinase
(MODY2)
Dominant
(may not be
diagnosed in
parents as mild)
152 10 (0–18) 11 (5.5–16) Usually incidental ﬁnding at diagnosis
Fasting glucose in range 5.5–8 mmol/l
Small increment in an OGTT (2–0 h
usually < 3.5 mmol/l)
Little deterioration in glycaemia with age
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MODY and relative prevalence in UK [1] is shown in Table
1. Unfortunately, no similar data are available in the Middle
East. There is one study postulating MODY as a presentation
in ‘‘Non Insulin dependent Diabetes’’ presenting in young
adults in Saudi Arabia [26], but no genetic testing was con-
ducted. A case report of the ﬁrst family of MODY in Saudi
was reported by our group in 2008 [27]. The case presented
with hyperglycemia for many months, as noted by the mother,
who was also diabetic. The child had normal BMI, no acan-
thosis nigricans and positive family history of diabetes in fam-
ily. Her antibody screen was negative, and genetic diagnosis
revealed HNF 4a mutation in the child, one affected brother
and her father who also had diabetes. A younger sister had
the mutation but was euglycemic.
Therefore, we feel that awareness of the diagnosis and clin-
ical ﬁndings will lead to the suspicion of MODY and earlier
diagnosis.3. Treatment of MODY
As previously mentioned, monogenic forms of diabetes are a
group of disorders with distinct clinical features and patho-
physiology. Therapy would therefore be directed towards the
metabolic condition of the patient, and individualized accord-
ing to the speciﬁc diagnosis and possible outcome.
Diagnosis of cases with glucokinase mutation may be difﬁ-
cult in children, as previously mentioned, due to mild inciden-
tal fasting hyperglycaemia. Currently there appears to be no
beneﬁt in treating patients in the pediatric age group, as fasting
hyperglycemia remains stable even without treatment, with
HbA1c being just above the acceptable range [25]. Microvascu-
lar and macrovascular complications are rarely seen, even
without treatment in these patients [28].
The real challenge is to treat patients with HNF 1a muta-
tions who were previously diagnosed as type 1, and started
on insulin. Once molecular diagnosis is available, the possibil-
ity of discontinuing insulin needs to be discussed with the fam-
ily [29]. In our experience, most pediatricians would prefer to
gradually reduce insulin doses before introducing oral
hypoglycemics.Patients with HNF 1a usually respond to sulphonylurea in
much lower doses than those used for type 2 treatment [30].
Patients may even be managed by diet initially, but this will
need close follow up in terms of adherence, to avoid the dete-
rioration of metabolic control. Families should be advised that
the need for treatment is expected, as progressive deterioration
of beta cell function is anticipated. They can be maintained on
sulfonylurea for a long time, with very good control. Insulin
may be needed in some cases.
Patients with mutations of HNF 4a would also beneﬁt from
sulfonylurea, but would be expected to require insulin should
beta cell dysfunction progress [31].4. Recommendations for follow up
There are no current guidelines for the management of MODY
in children and young adults. Stride et al. [25] provided a mod-
el for progression for HNF 1a and HNF 4a (being clinically
similar) as well as GKD.
Therefore, the recommendations that could be drawn are
that patients with glucokinase may not need treatment and
could just be followed up by serial fasting blood glucose. We
suggest serial glycated hemoglobin may be helpful to recognize
continued high blood glucose that would indicate remote pos-
sibility of microvascular or macrovascular complications (Figs.
1 and 2).
HNF 1a and HNF 4a, however, need to be followed up and
treated as mentioned above. These types are known to be asso-
ciated with microvascular and macrovascular complications,
and therefore I postulate that the same recommendations as
those for type 1 diabetes be followed.
It should be noted that current knowledge of prognosis and
long term follow up for these conditions remain limited, due to
smaller number of patients diagnosed when compared to type
1 and type 2 diabetes. The case for the pediatric population is
even worse when there are no randomized controlled trials for
the management of these cases in the pediatric age group.
Most data is extracted from the adult population, and few long
term studies are available so far.
We would therefore recommend that children and young
adults with HNF 1a and HNF 4a mutations be followed up
Figure 1 When to supect MODY?
Figure 2 When is type 1 diabetes most likely?
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research is available to allow special guidelines for this group
of patients.
5. Implications for other family members
With the diagnosis of any genetic disorder comes the question
of testing other family members and the implications of a po-sitive test. Adults have the legal right to consent to be tested
for genetic disorders and know if they are affected or non af-
fected carriers, or free from the disorder. They can then make
informed choices about jobs, partner’s future pregnancies, etc.
However, these tests, when undertaken, need to be under the
guidance and counseling of health care professionals who are
experts in the ﬁeld of genetic disorders, and can provide reli-
able information. The ﬁnancial burden of these tests on the
health care authorities needs to be taken into account as well.
Minors, however, present a further challenge. Parental con-
sent from biological parents or individuals with parental
responsibilities needs to be sought in all situations. Unless
the child is clearly affected by a genetic condition and molecu-
lar diagnosis will aid diagnosis and guide treatment, ethically
genetic testing can be a problem. For example, a genetic disor-
der may be manifest at a later stage in life, and the knowledge
of its possibility will limit life choices for the child unnecessar-
ily. On the other hand, knowledge of a condition that may not
have presented clinically yet may initiate early follow up and
delay, or prevent complications.
Therefore, offering genetic testing to families is dependent
on the nature of the disease and what is known of its mode
of inheritance and natural course. In cases of monogenic dia-
betes, it is our view, that all family members would beneﬁt
from screening by OGTT in cases of HNF mutation, and this
is also recommended by Stride et al. [25]. GKD patients’ fam-
ily members however would beneﬁt from only serial fasting
blood glucose estimation.
Those positive by screening can be offered genetic testing.
Females in the child bearing period would generally beneﬁt,
as they would be prone to diabetes associated with pregnancy.
6. Recommendations for future research
We recommend that cases of suspected familial diabetes seek
genetic testing for common forms of MODY. Collaboration
and communication between different centers in different
countries in the same region will allow a larger number of pa-
tients to be identiﬁed, and therefore, follow up and prognostic
conclusions can be drawn more effectively. OGTTs can be per-
formed on patients in specialized centers, to allow for guidance
on the molecular genetic testing of suspected cases. Insulin
should not be denied to any child or young adult with newly
diagnosed diabetes, whose metabolic condition is not stable,
awaiting OGTT or genetic studies.
7. Summary
The incidence of monogenic forms of diabetes has not been
identiﬁed in Saudi Arabia. In our experience of working with
children and young adults with diabetes, our group has identi-
ﬁed one family and reported it. Whether there are more cases
undiagnosed remains unknown. More awareness of the disor-
der is needed for better diagnosis and management.
Therefore, as an answer to our initial question, testing for
MODY should not be considered routinely. It should be of-
fered to select cases, where clinical and biochemical indicators
dictate. We propose the algorithm in this work as an initial
framework, which can be reviewed and modiﬁed in the future.
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